Clinical trials: First-line Treatment
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Pancreatic Adenocarcinoma Metastatic
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
This is a multi-center, open-label， randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Penpulimab combined with Anlotinib and Nab-paclitaxel plus Gemcitabine (PAAG ) versus AG…
- Trial name
- RCT-PAAG (NCT06051851)
- Testing
- Penpulimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Periorbital Wrinkles
Safety and Efficacy of XP200 Radiofrequency Treatment of Wrinkles
To evaluate the wrinkle-reducing effects of 3.25-MHz radiofrequency (RF) energy delivered in 4 weekly applications to human periorbital skin area by grating pre- and 90-days post treatment photographs on the Fitzpatrick Wrinkle…
- Trial name
- NCT01795417
- Testing
- RF XP200, XP200 RF device
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Iadademstat + SBRT With Atezo in ES-SCLC
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor…
- Trial name
- TIARA (NCT07113691)
- Testing
- Iadademstat, Atezolizumab, SBRT
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Non-small Cell Lung Cancer, First-line Treatment
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
This prospective, unicentric, open-labe phase I study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of…
- Trial name
- NCT03987867
- Testing
- CIK cell, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Alopecia
LLLT for Alopecia of the Eyebrow in Women
The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system…
- Trial name
- NCT04897555
- Testing
- LLLT
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Non-small Cell Lung Cancer
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the…
- Trial name
- NCT06403111
- Testing
- Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Changzhou No.2 People's Hospital